I didn't say it was.
That falls within the jurisdiction. In this particular situation, discussions have been going on since about 2006 on the 60-40 arrangement. When we purchased the antivirals, that was what our cover was, the 60-40 with provinces and territories. On behalf of the provinces, we also retained a contract with GSK. We have invested approximately $17 million to retain a contract with GSK on behalf of the provinces and territories to purchase vaccines within Canada.
As to what's happening in the United States in terms of their timeline and stuff, the timelines of Canada and the United States are quite close. What I've said before is that we have a window of opportunity here within Canada to examine the situations and cases we have seen in Canada, the severity of some of those cases, and so on, to have a good understanding of prioritizing who will receive the vaccine.
That's an important point. We don't need to rush into it.